These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21132496)

  • 1. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.
    Kawashima H; Itoh A; Ohno E; Nakamura M; Miyahara R; Ohmiya N; Hara K; Kanamori A; Itoh T; Taki T; Hirai T; Hashimoto S; Takeda K; Goto H; Hirooka Y
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):677-83. PubMed ID: 21132496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane C; Okusaka T; Furuse J; Ishii H; Ueno H; Ikeda M; Nakachi K; Najima M; Ogura T; Suzuki E
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):313-9. PubMed ID: 18398614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure.
    Okuno M; Mukai T; Iwata K; Takagi A; Ito Y; Ohashi Y; Tezuka R; Iwasa Y; Iwata S; Tomita E
    Med Oncol; 2024 Jul; 41(8):195. PubMed ID: 38967720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
    Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Ito Y; Sasahira N; Hirano K; Tsujino T; Toda N; Tada M; Omata M; Koike K
    Invest New Drugs; 2012 Apr; 30(2):708-13. PubMed ID: 20924641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A partial response to S-1 as second-line chemotherapy in a patient with unresectable pancreatic cancer].
    Egawa T; Ohashi M; Ito Y; Mihara K; Takahashi T; Hayashi S; Nagashima A
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2422-4. PubMed ID: 20037443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1.
    Morizane C
    Jpn J Clin Oncol; 2007 Dec; 37(12):973. PubMed ID: 18211987
    [No Abstract]   [Full Text] [Related]  

  • 8. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.
    Todaka A; Fukutomi A; Boku N; Onozawa Y; Hironaka S; Yasui H; Yamazaki K; Taku K; Machida N; Sakamoto T; Tomita H
    Jpn J Clin Oncol; 2010 Jun; 40(6):567-72. PubMed ID: 20189975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
    Takahara N; Isayama H; Nakai Y; Ishigami H; Satoi S; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Yamaguchi H; Tada M; Kitayama J; Watanabe T; Koike K
    Invest New Drugs; 2016 Oct; 34(5):636-42. PubMed ID: 27339809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
    Sudo K; Yamaguchi T; Nakamura K; Denda T; Hara T; Ishihara T; Yokosuka O
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):249-54. PubMed ID: 20352216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
    Ueno M; Okusaka T; Omuro Y; Isayama H; Fukutomi A; Ikeda M; Mizuno N; Fukuzawa K; Furukawa M; Iguchi H; Sugimori K; Furuse J; Shimada K; Ioka T; Nakamori S; Baba H; Komatsu Y; Takeuchi M; Hyodo I; Boku N
    Ann Oncol; 2016 Mar; 27(3):502-8. PubMed ID: 26681680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study.
    Togawa A; Yoshitomi H; Ito H; Kimura F; Shimizu H; Ohtsuka M; Yoshidome H; Kato A; Sawada S; Miyazaki M
    Int J Clin Oncol; 2007 Aug; 12(4):268-73. PubMed ID: 17701005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
    Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
    Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
    Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Hara T; Denda T; Tawada K; Imagumbai T; Araki H; Sakai M; Hatano K; Kawakami H; Uno T; Ito H; Yokosuka O
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):119-25. PubMed ID: 20605363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
    Uwagawa T; Sakamoto T; Abe K; Okui N; Hata D; Shiba H; Futagawa Y; Aiba K; Yanaga K
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):191-6. PubMed ID: 25422155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
    Go SI; Lee SC; Bae WK; Zang DY; Lee HW; Jang JS; Ji JH; Kim JH; Park S; Sym SJ; Yang Y; Jeon SY; Hwang IG; Oh SY; Kang JH
    Eur J Cancer; 2021 Nov; 157():21-30. PubMed ID: 34464782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
    Suzuki E; Ikeda M; Okusaka T; Nakamori S; Ohkawa S; Nagakawa T; Boku N; Yanagimoto H; Sato T; Furuse J
    Cancer Chemother Pharmacol; 2013 May; 71(5):1141-6. PubMed ID: 23525694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine plus S-1 for metastatic pancreatic cancer.
    Zhu H; Yi C; Zhao Y; Gou H
    Medicine (Baltimore); 2018 Oct; 97(41):e12836. PubMed ID: 30313120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan.
    Nakai Y; Isayama H; Sasaki T; Sasahira N; Kogure H; Hirano K; Tsujino T; Ijichi H; Tateishi K; Tada M; Omata M; Koike K
    Jpn J Clin Oncol; 2010 Aug; 40(8):774-80. PubMed ID: 20462979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A Case of Gemcitabine Refractory Lung Metastasis after Distal Pancreatectomy for Pancreatic Cancer, Effectively Treated with S -1 as Second Line Chemotherapy].
    Omori K; Wakabayashi K; Suematsu Y; Suda H; Hiratsuka M; Takahashi M; Saito H; Ishibashi Y; Morita A; Ito Y
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1582-4. PubMed ID: 26805103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.